📰 Servier Group News
Page 4 - Servier Group News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Servier Group. Real-time updates on events, politics, business and more.
June 1, 2022
Wide range of research across tumor types underscores Serviers commitment to discovering novel approaches to addressing difficult-to-treat cancers Phase 3...
May 25, 2022
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and...
May 25, 2022
TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based
May 25, 2022
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and...
March 10, 2022
- TIBSOVO is an inhibitor of the mutated isocitrate dehydrogenase-1(IDH1) enzyme - TIBSOVO is the first IDH1 mutation specific targeted therapy submitted in Europe - The submission
March 10, 2022
-- TIBSOVO is an inhibitor of the mutated isocitrate dehydrogenase-1(IDH1) enzyme -- TIBSOVO is the first...
January 18, 2022
PARIS, Jan. 18, 2022 /PRNewswire/ -- Servier, an independent global pharmaceutical group, published its results for the 2020/21 financial year, en...
January 18, 2022
/PRNewswire/ -- Servier, an independent global pharmaceutical group, published its results for the 2020/21 financial year, ending on September 30, 2021, and...
January 18, 2022
/PRNewswire/ -- Servier, an independent global pharmaceutical group, published its results for the 2020/21 financial year, ending on September 30, 2021, and...
January 18, 2022
- Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates) - Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current